Table 3.
Common opportunistic infections in the study population at 3, 6 and 12 months after presentation to care
| Infections | 3 months | 6 months | 12 months | |||
|---|---|---|---|---|---|---|
| n/N | % | n/N | % | n/N | % | |
| Pulmonary tuberculosis | 218/1046 | 20.8 | 64/213 | 30.1 | 36/144 | 25.0 |
| Bacterial pneumonia | 116/1044 | 11.1 | 25/213 | 11.7 | 23/143 | 16.1 |
| Herpes zoster | 169/1041 | 16.2 | 26/213 | 12.2 | 14/143 | 9.8 |
| Skin Kaposi sarcoma | 98/1042 | 9.4 | 16/213 | 7.5 | 13/143 | 9.1 |
| Candidiasis | 41/1045 | 3.9 | 11/213 | 5.2 | 13/143 | 9.1 |
| Cryptococcal Meningo-encephalitis | 49/1047 | 4.7 | 10/215 | 4.7 | 5/144 | 3.5 |
| Cerebral toxoplasmosis | 85/1051 | 8.1 | 10/213 | 4.7 | 11/144 | 7.6 |
| Tuberculous meningitis | 25/1047 | 2.4 | 8/213 | 3.8 | 6/137 | 4.2 |
| HIV encephalitis | 27/1047 | 2.6 | 1/213 | 0.50 | 7/143 | 4.9 |
| Pulmonary aspergillosis | 1/1044 | 0.10 | 0/213 | 0.00 | 0/143 | 0.00 |
| Pulmonary Kaposi sarcoma | 12/1044 | 1.2 | 13/213 | 6.1 | 9/143 | 6.3 |
| Microsporidia | 1/1043 | 0.10 | 1/213 | 0.50 | 1/143 | 0.70 |
| Isosporidia | 3/1043 | 0.30 | 2/213 | 1.0 | 2/143 | 1.4 |
| Cryptosporidiosis | 2/1043 | 0.20 | 0/213 | 0.00 | 2/143 | 1.40 |